Integumen PLC - New Labskin AI contracts; additional lab space
AIM share code: SKIN
("Integumen" or "Company")
Three new Labskin AI contracts, including Cannabidiol infused tampons to relieve cramp
Addition of state-of-the-art Labskin laboratories to meet growing demand
Integumen today announces that Labskin AI, the virtual laboratory platform, has entered into testing agreements with three new clients - a leading chain drug store, a European provider of beauty and household products, and "Femcare" female hygiene product brand - Your Daye, "the world's first cramp-fighting tampon" infused with Cannabidiol (CBD). The contracts are worth c£290,000 in aggregate, with individual values ranging from
Labskin laboratory expansion
To accommodate these agreements, and further contracts under negotiation, the Company also announces that it is increasing the Group's Labskin laboratory capacity by 50%. This increase is in addition to the previously announced expansion earlier this year (see RNS dated
In line with the Group's strategy, the Company continues to make rapid progress up the value chain by entering into larger contracts for Labskin AI services. This growing demand is a result of the prohibition of animal testing and the requirement of client companies to comply with EU Regulation 2017/745 Rule 21.
"These breakthrough agreements are the first for our Labskin AI services confirming demand exists from high-street drug stores, household chemical and beauty product manufacturers and novel skin care brand owners to comply with EU Directive 2017/745 Rule 21. Following recent changes to our strategy to target larger, higher-value contracts, these new agreements highlight the progress we are making as we set the business up for greater expansion.
"The contract with Daye validates our expertise in CBD testing, already demonstrated in the development of protocols for the Company's STOER For Men skin care range, earlier this year, and puts Labskin at the forefront of CBD regulatory compliance testing for manufacturers wishing to sell CBD infused consumer products."
"We are delighted to begin collaboration with the team at Labskin to explore the impact of CBD on "Your Daye" female hygiene products. With 90% of women experiencing period pain at some stage in their lifetime, 52% miss a day of work because of it in and these tests are expected to deliver results fast and speed up time to market to address this unmet need."
| || |
+44 (0) 7340 055 643
| || |
+44 (0) 113 370 8974
| || || |
+44 (0) 20 3621 4120
Integumen is a vertically integrated business, collaborating its Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skincare, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.
The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.
Daye creates category-defining products and services that set a new standard for medical research and scientific innovation.
Daye has set out to build a new brand for female health products "designed with women in mind." The start-up's first product is a newly developed tampon that uses CBD to help tackle period cramps (or dysmenorrhea) as an alternative to traditional painkillers (CBD is the extract derived from the flower of the industrial hemp plant, a legal relative to marijuana). Daye recently announced
This information is provided by RNS, the news service of the
Quick facts: DeepVerge plc
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE